THREE NEW MUTATIONS FOUND IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT TO TYROSINE KINASE INHIBITORS (TKI)

被引：0
|
作者：
Mascarenhas, C. Couto [1 ]
机构：
[1] Univ Estadual Campinas, Campinas, SP, Brazil
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1469
引用
收藏
页码：572 / 572
页数：1
相关论文
共 50 条
  • [1] Tyrosine kinase inhibitors (TKI): a new revolution in the treatment of chronic myeloid leukemia (CML)
    Aviles-Vazquez, Socrates
    Chavez-Gonzalez, Antonieta
    Mayani, Hector
    GACETA MEDICA DE MEXICO, 2013, 149 (06): : 646 - 654
  • [2] Dynamics of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia (CML) after treatment with one, two or three tyrosine kinase inhibitors (TKI).
    Jabbour, Elias
    Jones, Dan
    Kantarjian, Hagop
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Giles, Francis
    Wierda, William
    Cortes, Jorge
    BLOOD, 2006, 108 (11) : 225A - 225A
  • [3] Treatment of chronic myeloid leukemia (CML) in children and adolescents in the era of tyrosine kinase inhibitors (TKI)
    Suttorp, M.
    Tauer, J. T.
    Nowasz, C.
    Krumbolz, M.
    von Neuhoff, N.
    Glauche, I
    Schlegelberger, B.
    Metzler, M.
    Thiede, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 301 - 301
  • [4] EFFICACY OF SUBCUTANEOUS HOMOHARRINGTONINE IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT TO TYROSINE KINASE INHIBITORS (TKI) AND HARBORING A BCR-ABL MUTATION
    Marin, D.
    Maloisel, F.
    Legros, L.
    Nicolini, F. E.
    Roy, L.
    Rousselot, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 56 - 56
  • [5] Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy
    Barber, Mary C.
    Mauro, Michael J.
    Moslehi, Javid
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2017, : 110 - 114
  • [6] Incidence of Secondary Malignancies in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Era of Tyrosine Kinase Inhibitors (TKI)
    Sasaki, Koji
    Kantarjian, Hagop M.
    O'Brien, Susan M.
    Ravandi, Farhad
    Konopleva, Marina
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Wierda, William G.
    Daver, Naval
    Ferrajoli, Alessandra
    Takahashi, Koichi
    Jain, Preetesh
    Rios, Mary B.
    Pierce, Sherry
    Jabbour, Elias J.
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [7] Treatment Responses in Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitors (TKI) Therapy
    Mir, Ahmed Ali
    Mir, Abdur Rehman
    Rehmat, Uswah
    Shakoor, Ifra
    Amjad, Farhan
    Khalid, Muhammad
    Mallhi, Tauqeer Hussain
    Laique, Talha
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2021, 15 (09): : 2358 - 2360
  • [8] Cause of Death in Resistant and Advanced Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs).
    McGarry, Lisa J.
    Burudpakdee, Chakkarin
    Gala, Smeet
    Seetasith, Arpamas
    Nanavaty, Merena
    Huang, Hui
    BLOOD, 2014, 124 (21)
  • [9] Estimated Glomerular Filtration Rate Changes In Patients (Pts) With Chronic Myeloid Leukemia (CML) Treated With Tyrosine Kinase Inhibitors (TKI)
    Yilmaz, Musa
    Kantarjian, Hagop M.
    Quintas-Cardama, Alfonso
    O'Brien, Susan
    Burger, Jan A.
    Ferrajoli, Alessandra
    Borthakur, Gautam
    Ravandi, Farhad
    Pierce, Sherry
    Jabbour, Elias
    Cortes, Jorge E.
    BLOOD, 2013, 122 (21)
  • [10] ADHERENCE TO TYROSINE KINASE INHIBITORS (TKI) IN CHRONIC MYELOID LEUKEMIA (CML) SEEMS TO BE RELATED TO DURATION OF TREATMENT AND TYPE
    De Almeida, M. H.
    Barbosa Pagnano, K. B.
    Sanches Souza, H. A.
    Souza, C. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 343 - 343
12345